Table 2.

Univariate and multivariate analysis for cumulative incidence of CMV reactivation

Variables	Univariate analysis			Multivariate analysis
	HR	95% CI	P	HR	95% CI	P
Underlying disease*
Acute lymphoblastic leukemia	0.93	0.87-0.99	.035	1.01	0.94-1.09	.79
Myelodysplastic syndromes	1.06	0.99-1.14	.071	1.03	0.96-1.10	.38
CML	0.83	0.72-0.95	.009	0.89	0.78-1.02	.10
Patient age ≥50 y	1.38	1.31-1.46	<.001	1.30	1.22-1.38	<.001
Donor age ≥50 y	0.87	0.80-0.94	<.001	0.97	0.88-1.07	.52
Patient sex, male	1.01	0.95-1.06	.85	0.97	0.90-1.04	.35
Donor sex, male	1.03	0.98-1.09	.22	1.07	0.99-1.16	.10
Female donor/male recipient	1.00	0.94-1.07	.89	1.07	0.96-1.19	.22
Recipient/donor CMV serology†
Positive/positive	2.17	1.95-2.42	<.001	2.20	1.96-2.47	<.001
Positive/negative	2.63	2.36-2.93	<.001	2.48	2.22-2.76	<.001
Negative/positive	1.11	0.95-1.30	.20	1.16	0.98-1.36	.080
Disease risk (high)	1.04	0.99-1.09	.15	0.94	0.89-1.00	0.042
PS (poor)	1.03	0.94-1.14	.51	0.95	0.86-1.05	.30
Stem cell source‡
PBSC	0.88	0.82-0.95	<.001	1.02	0.91-1.14	.72
CB	1.09	1.03-1.15	.005	0.86	0.79-0.93	<.001
Transplant from unrelated donor	1.29	1.21-1.37	<.001	1.27	1.13-1.42	<0.001
HLA disparity (mismatch)	1.51	1.43-1.59	<.001	1.46	1.37-1.55	<.001
Conditioning (reduced intensity)	1.25	1.18-1.32	<.001	1.03	0.97-1.10	.34
TBI	1.06	1.01-1.13	.032	1.12	1.06-1.19	<.001
GVHD prophylaxis
Tacrolimus-based regimen§	1.13	1.06-1.19	<.001	0.90	0.84-0.96	.002
Mycophenolate mofetil use	0.97	0.89-1.05	.41	0.88	0.80-0.96	.006
TCD in vivo	1.73	1.57-1.89	<.001	1.64	1.48-1.82	<.001
Transplant year (2004-2010)¶	1.10	1.04-1.16	<.001	1.12	1.06-1.18	<.001

^*Acute myeloid leukemia was treated as reference.

^†Negative/negative CMV serology was treated as reference.

^‡Bone marrow transplantation was treated as reference.

^§Cyclosporine-based regimen was treated as reference.

^¶​Transplant year (2011-2016) was treated as reference.